INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) EXPANDS LEADERSHIP TEAM

Published Oct 28, 2015

BETSY LANE JOINS ISPOR AS CHIEF MARKETING & COMMUNICATIONS OFFICER 

Princeton, NJ—October 28, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced that Betsy Lane has been appointed director and chief marketing and communications officer for the organization. Lane will lead ISPOR’s global marketing and communications efforts to help further advance the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. Lane has over 25 years’ experience in the life sciences industry. Prior to joining ISPOR, she served as senior vice president, marketing and communications at Publicis Touchpoint Solutions. Previously, she worked for several medical advertising agencies leading agency teams primarily focused on specialty product launches in the oncology, endocrinology, CNS, and dermatology therapeutic areas. Lane began her career working as a pharmaceutical sales representative. While at Johnson & Johnson, she served in a variety of increasingly significant roles, including divisional sales manager and product manager. “We are excited to have Betsy join the ISPOR team,” stated Nancy Berg, chief executive officer and executive director. “Our organization has grown tremendously over the years and we believe that Betsy’s experience will help us to further our mission by more effectively communicating the great work that ISPOR does day in and day out.”

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×